Lupin Stock Price - ₹2,132.00 | Healthcare

‌
‌
‌

The Quarter story

The two most recent quarterly results, compared side-by-side.

Lupin delivers strong top-line and margin growth driven by US and India recovery, though net income margins face slight pressure.

Consolidated net sales grew from ₹61,638 Cr in Q1 FY26 to ₹82,172 Cr in Q1 FY27, showing consistent top-line expansion.

Net income margin fell from 19.8% in Q1 FY26 to 17.2% in Q1 FY27, indicating pressure on bottom-line profitability.

EBITDA margin expanded from 26.6% in Q1 FY26 to 30.0% in Q1 FY27, reflecting strong operational efficiency.

API revenue mix contracted from 4% in Q1 FY26 to 3% in Q1 FY27, showing a shrinking contribution from the segment.

US revenue surged from ₹24,041 Cr in Q1 FY26 to ₹34,348 Cr in Q1 FY27, driven by sustained demand in the American market.

India revenue mix dropped from 34% in Q1 FY26 to 29% in Q1 FY27, reflecting relative share dilution amid global growth.

India sales rebounded from ₹19,082 Cr in Q4 FY26 to ₹23,796 Cr in Q1 FY27, signaling a strong domestic recovery.

Other operating income declined from ₹1,045 Cr in Q1 FY26 to ₹597 Cr in Q1 FY27, highlighting volatile non-core earnings.

R&D spending climbed from ₹4,844 Cr in Q1 FY26 to ₹6,077 Cr in Q1 FY27, supporting ongoing innovation efforts.

APAC sales fluctuated and settled at ₹3,142 Cr in Q1 FY27, down slightly from ₹3,158 Cr in Q1 FY26, showing uneven regional performance.

‌
‌
‌

In the news

Lupin shares recover from 6-month low after Citi downgrade

Lupin wins patent infringement case against Vertex for Kalydeco

Lupin partners Tenpoint for €75M YUVEZZI ophthalmic therapy in EU

Lupin shares in focus after USFDA approval for Pitolisant Tablets

Lupin faces mixed ratings: Motilal Oswal Neutral, ICICI Securities Reduce

Lupin gets USFDA approval for Sodium Zirconium Cyclosilicate

Lupin's Q1 FY2027: Margin Magic Behind ₹8,217 Crore Revenue Surge

Lupin Q1 profit jumps 16% to ₹1,417 cr, shares hit 7-week low

Lupin launches Sugammadex Injection in US market

Lupin launches Sugammadex Injection after USFDA approval

Lupin spins off oncology programs to Kaveri Therapeutics for $1.6M stake

US recalls 2.5M India-made eye drops over contamination

Banking Q1 Results: Strong Credit Growth Drives Private Sector Surge

Lupin gets EMA approval for pediatric NaMuscla dosage expansion

Banking Stocks Mixed: HDFC Bank, Axis Bank Lead Updates

Lupin gains 2.21% as US FDA approves generic prostate cancer drug

Lupin launches generic hypertension drug targeting $53.5M market

Lupin launches Luforbec inhaler in Spain via ERN partnership

Lupin shares rise 1.68% after USFDA approval for Ranluspec biosimilar

Lupin gets USFDA approval for Ranluspec biosimilar and Eribulin injection